Valuation: Intervacc AB

Market Cap 344M 35M 30.52M 28.74M 26.18M 49.08M 3.35B 49.14M 133M 1.71B 131M 129M 5.51B P/E 2026 *
-0.9x
P/E 2027 * -0.9x
Enterprise Value 255M 25.95M 22.63M 21.31M 19.41M 36.39M 2.49B 36.43M 98.37M 1.27B 97.48M 95.32M 4.09B EV / Sales 2026 *
12.2x
EV / Sales 2027 * 9.44x
Free-Float
80.66%
Yield 2026 *
-
Yield 2027 * -
1 day-1.09%
1 week-0.50%
Current month-5.75%
1 month-11.44%
3 months-24.43%
6 months+8.59%
Current year+8.12%
1 week 0.98
Extreme 0.98
1.05
1 month 0.97
Extreme 0.967
1.14
Current year 0.57
Extreme 0.572
1.46
1 year 0.57
Extreme 0.572
1.46
3 years 0.57
Extreme 0.572
10.46
5 years 0.57
Extreme 0.572
76
10 years 0.57
Extreme 0.572
95.5
Manager TitleAgeSince
Chief Executive Officer 70 05/02/2026
Director of Finance/CFO - 06/02/2020
Chief Tech/Sci/R&D Officer - 11/06/2020
Director TitleAgeSince
Chairman 56 13/05/2026
Director/Board Member 72 01/01/2024
Director/Board Member 68 01/01/2025
Date Insider Type Main position Quantity % Market Cap. Importance
23/02/25 Free

Chief Financial Officer

929,208 1.2269%
17/02/25 Buy

Chief Executive Officer

135,000 0.1783%
17/02/25 Sell

Chief Executive Officer

278,820 0.3681%
Change 5-day change 1-year change 3-year change Capi.($)
-1.09%-0.50%-3.76%-74.42% 35M
+4.98%+5.73%+54.45%+113.83% 74.33B
-1.54%-0.42%+35.49%+79.14% 62.26B
-0.66%+6.97%+31.36%+23.45% 27.72B
-0.60%+0.45%-16.94%+360.28% 26.42B
+4.07%+4.70%+2.54%-3.26% 24.62B
+1.02%+5.72%+25.20%-10.12% 20.72B
-2.54%-3.36%+149.64%+324.48% 15.01B
+2.25%+1.74%+46.26%+169.51% 14.18B
+1.21%-1.95%-10.68%+812.30% 13.48B
Average +0.69%+1.10%+31.36%+179.52% 27.88B
Weighted average by Cap. +1.33%+2.26%+35.95%+148.83%

Financials

2026 *2027 *
Net sales 21M 2.14M 1.86M 1.75M 1.6M 2.99M 205M 3M 8.09M 104M 8.02M 7.84M 336M 30M 3.05M 2.66M 2.51M 2.28M 4.28M 292M 4.28M 11.56M 149M 11.46M 11.2M 480M
Net income -82.45M -8.38M -7.31M -6.88M -6.27M -11.76M -803M -11.77M -31.78M -409M -31.49M -30.79M -1.32B -83.65M -8.51M -7.42M -6.98M -6.36M -11.93M -815M -11.94M -32.24M -415M -31.95M -31.24M -1.34B
Net Debt -89M -9.05M -7.89M -7.43M -6.77M -12.69M -867M -12.7M -34.3M -442M -33.99M -33.24M -1.43B -61M -6.2M -5.41M -5.09M -4.64M -8.7M -594M -8.71M -23.51M -303M -23.3M -22.78M -977M
Logo Intervacc AB
Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Company’s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.
Employees
16
Date Price Change Volume
22/09/26 SEK 0.9990 -1.09% 271,462
21/09/26 SEK 1.010 0.00% 212,065
18/09/26 SEK 1.010 +1.41% 153,786
17/09/26 SEK 0.9960 +0.50% 79,996
16/09/26 SEK 0.9910 -1.29% 83,041

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IVACC Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!